18 Apr 2023 |
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
|
17 Apr 2023 |
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
|
17 Apr 2023 |
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
|
13 Apr 2023 |
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
|
13 Apr 2023 |
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
|
12 Apr 2023 |
Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda
|
05 Apr 2023 |
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
|
05 Apr 2023 |
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
|
04 Apr 2023 |
JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease
|
30 Mar 2023 |
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
|
29 Mar 2023 |
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
|
28 Mar 2023 |
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
|
28 Mar 2023 |
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
|
28 Mar 2023 |
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
|
27 Mar 2023 |
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
|
23 Mar 2023 |
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
|
21 Mar 2023 |
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
|
21 Mar 2023 |
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
|
13 Mar 2023 |
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
|
13 Mar 2023 |
Pfizer Invests $43 Billion to Battle Cancer
|
08 Mar 2023 |
Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
|
05 Mar 2023 |
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
|
02 Mar 2023 |
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
|
01 Mar 2023 |
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
|
23 Feb 2023 |
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
|